📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? (2017)

First Author: Reuter A

Attributed to: A phase III cluster randomised placebo-controlled trial to assess the efficacy of preventive therapy in child and adolescent contacts of MDR-TB funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.5588/ijtld.17.0468

PubMed Identifier: 29037291

Publication URI: http://europepmc.org/abstract/MED/29037291

Type: Journal Article/Review

Parent Publication: The International Journal of Tuberculosis and Lung Disease

Issue: 11

ISSN: 1027-3719